• Indexing List

IP International Journal of Orthopaedic Rheumatology


Zolindronic Acid in Osteoporosis- A Dexa Study


Full Text PDF Share on Facebook Share on Twitter


Author Details: Muthukumar Balaji, Sathish Devadoss, A Devadoss, Sreekanth Gunti

Volume : 1

Issue : 1

Online ISSN : 2581-9151

Print ISSN : 2581-8112

Article First Page : 1

Article End Page : 5


Abstract

Background: Osteoporosis a systemic skeletal disease characterized by low bone mass and micro architectural deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in fracture risk. We present our study analyzing the effect of Intravenous zolendronic therapy in osteoporotic individuals using the Dual Energy X-ray Absorptiometry Scan.
Materials and method: All patients above 50 yrs of age with osteoporosis measured by DEXA Scan of Lumbar Spine BMD (T-score<-2.5). Patients who were admitted or treated on outpatient basis from January 2009 to January 2010 have been included in this study based on inclusion and exclusion criteria. All patients were started on Intravenous Zolendronic acid after a BMD scan with T-score less than -2.5. As defined by WHO in osteoporosis, Inj. Zolendronic Acid was given once a year for 3 years.
Results: The mean age for the study group was 67.7 years of age (range 54 to 85 yrs). 12 patients in our study had improvement in BMD (t-score), of which 10 patients were females and 2 patients were males (all below the age of 65years). Among the 12 patients who had improvement in BMD proven by DEXA Scan, the percentage of actual improvement in BMD in these patients was an average of 11.62%.
Conclusion: Intravenous Zolendronic acid once every year has the best benefit when administered to osteoporotic individuals < 65yrs of age to improve BMD. Due to the better compliance of IV Zolendronic Acid, once yearly dose is preferable, when compared to oral Bisphosphonates.

Key words: Zolindronic acid, Osteoporosis, Dexa scan, Fragility fractures